Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

By sjmartinez • March 7, 2025

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study. Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07656-z. Epub ahead of print. PMID: 40050524.

Tags: breast cancer, event-free survival, GnRHa, Gonadotropin-releasing hormone agonists, Goserelin, Hematology/Oncology, Premenopausal, Publications, real-world evidence

Related Posts

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder[...]

Advancing precision health discovery in a genetically diverse health system

Haas R, Margolis MP, Wei A, Yamaguchi TN, Feng J, Tran T, Tozzo V, Queen KJ, Mootor MFE, Patil V, Broudy ME, Tung P, Alam[...]